• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

痉挛指数-肌萎缩侧索硬化症的开发和验证。

Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.

机构信息

Imperial College London, London, UK.

Swiss Paraplegic Research, Nottwil, Switzerland.

出版信息

Acta Neurol Scand. 2018 Jul;138(1):47-54. doi: 10.1111/ane.12910. Epub 2018 Feb 21.

DOI:10.1111/ane.12910
PMID:29468643
Abstract

OBJECTIVES

Spasticity is a common and disabling feature of amyotrophic lateral sclerosis (ALS). There are currently no validated ALS-specific measures of spasticity. The aim of this study was to develop and use a self-report outcome measure for spasticity in ALS.

METHODS

Following semi-structured interviews with 11 ALS patients, a draft scale was administered across ALS clinics in the UK. Internal validity of the scale was examined using the Rasch model. The numerical rating scale (NRS) for spasticity and Leeds Spasticity scale (LSS) were co-administered. The final scale was used in a path model of spasticity and quality of life.

RESULTS

A total of 465 patients (mean age 64.7 years (SD 10), 59% male) with ALS participated. Spasticity was reported by 80% of subjects. A pool of 71 items representing main themes of physical symptoms, negative impact and modifying factors was subject to an iterative process of item reduction by Rasch analysis resulting in a 20-item scale-the Spasticity Index for ALS (SI-ALS)-which was unidimensional and free from differential item functioning. Moderate correlations were found with LSS and NRS-spasticity. Incorporating the latent estimate of spasticity into a path model, greater spasticity reduced quality of life and motor function; higher motor function was associated with better quality of life.

CONCLUSIONS

The SI-ALS is a disease-specific self-report scale, which provides a robust interval-level measure of spasticity in ALS. Spasticity has a substantial impact on quality of life in ALS.

摘要

目的

痉挛是肌萎缩侧索硬化症(ALS)的常见且致残特征。目前尚无针对 ALS 痉挛的经过验证的特定评估方法。本研究的目的是开发和使用用于 ALS 痉挛的自我报告结局评估方法。

方法

在对 11 名 ALS 患者进行半结构化访谈后,在英国的 ALS 诊所中使用了一份草案量表。使用 Rasch 模型检查量表的内部有效性。同时还共同使用了数字评定量表(NRS)和利兹痉挛量表(LSS)。最终量表用于痉挛和生活质量的路径模型中。

结果

共有 465 名(平均年龄 64.7 岁(标准差 10),59%为男性)ALS 患者参与了研究。80%的患者报告有痉挛。一个包含 71 个项目的池,代表身体症状、负面影响和调节因素的主要主题,经过 Rasch 分析的迭代过程,以减少项目数量,最终形成一个 20 项的量表-肌萎缩侧索硬化症痉挛指数(SI-ALS),该量表是单维的,没有项目间功能差异。与 LSS 和 NRS 痉挛评分的相关性适中。将痉挛的潜在估计值纳入路径模型中,痉挛程度越高则生活质量和运动功能越低;运动功能越高则生活质量越好。

结论

SI-ALS 是一种疾病特异性的自我报告量表,为 ALS 中的痉挛提供了可靠的区间水平评估方法。痉挛对 ALS 患者的生活质量有重大影响。

相似文献

1
Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.痉挛指数-肌萎缩侧索硬化症的开发和验证。
Acta Neurol Scand. 2018 Jul;138(1):47-54. doi: 10.1111/ane.12910. Epub 2018 Feb 21.
2
Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study.肉毒杆菌毒素A治疗肌萎缩侧索硬化症痉挛的安全性和有效性:一项试点研究的结果
J Neurol. 2016 Oct;263(10):1954-60. doi: 10.1007/s00415-016-8223-z. Epub 2016 Jul 6.
3
Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).基于 Rasch 构建的肌萎缩侧索硬化症综合残疾量表(ROADS)的制定与验证。
JAMA Neurol. 2020 Apr 1;77(4):480-488. doi: 10.1001/jamaneurol.2019.4490.
4
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).使用四氢大麻酚:大麻二酚(THC:CBD)治疗肌痉挛的肌萎缩侧索硬化症(ALS)患者的真实世界经验。
BMC Neurol. 2019 Sep 7;19(1):222. doi: 10.1186/s12883-019-1443-y.
5
Correlation of falls in patients with Amyotrophic Lateral Sclerosis with objective measures of balance, strength, and spasticity.肌萎缩侧索硬化症患者跌倒与平衡、力量和痉挛客观测量指标的相关性。
NeuroRehabilitation. 2019;44(1):85-93. doi: 10.3233/NRE-182531.
6
Dyspnea in Amyotrophic Lateral Sclerosis: Rasch-Based Development and Validation of a Patient-Reported Outcome (DALS-15).肌萎缩侧索硬化症呼吸困难:基于 Rasch 的患者报告结局(DALS-15)的开发和验证。
J Pain Symptom Manage. 2018 Nov;56(5):736-745.e2. doi: 10.1016/j.jpainsymman.2018.08.009. Epub 2018 Aug 24.
7
Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.肌萎缩侧索硬化症/运动神经元病中痉挛状态的治疗
Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD004156. doi: 10.1002/14651858.CD004156.pub4.
8
Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.肌萎缩侧索硬化症/运动神经元病中痉挛的治疗
Cochrane Database Syst Rev. 2004(1):CD004156. doi: 10.1002/14651858.CD004156.pub2.
9
Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure.验证扩展型 ALS 功能评定量表的德文版作为一种患者报告的结局测量指标。
J Neurol. 2013 Sep;260(9):2242-55. doi: 10.1007/s00415-013-6955-6. Epub 2013 Jun 5.
10
Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.一项随机、双盲、安慰剂对照研究的研究方案,旨在评估基于大麻的药物提取物在减缓肌萎缩侧索硬化症或运动神经元病的疾病进展方面的疗效:EMERALD 试验。
BMJ Open. 2019 Nov 11;9(11):e029449. doi: 10.1136/bmjopen-2019-029449.

引用本文的文献

1
Advancing Future Amyotrophic Lateral Sclerosis Medicines by Incorporating The Patient Voice Into Patient-Centered Holistic Measurement Strategies for Clinical and Real-World Studies: Results from Targeted Literature Reviews.通过将患者声音纳入临床和真实世界研究的以患者为中心的整体测量策略来推进未来的肌萎缩侧索硬化症药物:靶向文献综述的结果
Neurol Ther. 2025 May 12. doi: 10.1007/s40120-025-00740-y.
2
Determinants and progression of stigma in amyotrophic lateral sclerosis/motor neuron disease.肌萎缩侧索硬化症/运动神经元病中耻辱感的决定因素及进展
Amyotroph Lateral Scler Frontotemporal Degener. 2025 May;26(3-4):192-202. doi: 10.1080/21678421.2024.2435969. Epub 2025 Jan 3.
3
Clinical Outcome Assessments for Spasticity: Review, Critique, and Recommendations.
痉挛的临床结局评估:综述、批判与建议
Mov Disord. 2025 Jan;40(1):22-43. doi: 10.1002/mds.30062. Epub 2024 Dec 4.
4
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).使用四氢大麻酚:大麻二酚(THC:CBD)治疗肌痉挛的肌萎缩侧索硬化症(ALS)患者的真实世界经验。
BMC Neurol. 2019 Sep 7;19(1):222. doi: 10.1186/s12883-019-1443-y.